Group 1 - The company plans to issue shares to a specific group, aiming to enhance its capital structure and improve financial stability [3][4][26] - The issuance is driven by high debt levels and the need for liquidity, with the company's debt-to-asset ratio reaching 75.91% as of March 31, 2025 [4][5][6] - The actual controller's confidence in the company's future is reflected in the full subscription of the shares by the controlling entity, which is expected to stabilize control and support future growth [3][7][26] Group 2 - The funds raised will be used to supplement working capital and repay debts, which is crucial for the company's operational continuity and financial health [4][21][24] - The issuance will lead to an increase in total shares and net assets, potentially diluting earnings per share in the short term, with projections indicating a basic earnings per share of -0.37 before and after the issuance [16][18][21] - The company has committed to measures to mitigate the impact of dilution on immediate returns, ensuring that shareholder interests are protected [23][25][26] Group 3 - The issuance process adheres to relevant regulations, including the Securities Law and the Management Measures for the Issuance of Securities by Listed Companies [10][11][12] - The pricing of the shares is set at 6.55 yuan per share, which is 80% of the average trading price over the previous 20 trading days [9][10] - The company will ensure that the funds are managed and utilized according to established regulations, enhancing transparency and efficiency in fund usage [24][26]

Group 1 - The company Tianyu Bio-Technology Co., Ltd. plans to issue shares to a specific group, with the aim of raising funds to supplement working capital and repay debts [2][11][14] - The issuance will involve a maximum of 71,028,297 shares, which is capped at 30% of the company's total share capital prior to the issuance [13][15] - The share price is set at 6.55 RMB per share, which is not less than 80% of the average trading price over the 20 trading days prior to the pricing benchmark date [12][29] Group 2 - The issuance is characterized as a related party transaction, as the shares will be fully subscribed by Shanghai Daoyun Asset Management Co., Ltd., controlled by the company's actual controller, Luo Weiguo [10][15] - The company has a high debt ratio, with figures of 59.13%, 74.51%, 77.96%, and 75.91% at the end of the reporting periods, indicating significant financial pressure [10] - The funds raised will be used entirely for operational needs and debt repayment, which is expected to optimize the company's capital structure and enhance its sustainability [11][14] Group 3 - The company aims to enhance its control stability through this issuance, as the actual controller's stake will increase, reflecting confidence in the company's future [10][11] - The issuance is not expected to change the company's control structure, as the actual controller will maintain a significant voting power post-issuance [15] - The company has established a profit distribution policy to ensure transparency and stability in shareholder returns, aligning with regulatory guidelines [4][10]